Brief: Shandong Boan Biotechnology Says Co And CP Pharmaceutical Qingdao Co Entered Into Agreement
10/01/2023 14:46
Jan 10 (Reuters) - Shandong Boan Biotechnology Co Ltd
6955.HK :
* COMPANY AND CP PHARMACEUTICAL QINGDAO CO ENTERED INTO
AGREEMENT
* DEAL TO GRANT OF EXCLUSIVE COMMERCIALIZATION RIGHTS OF
DENOSUMAB
INJECTION IN MAINLAND CHINA TO CP QINGDAO
Further company coverage: 6955.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shandong Boan Biotechnology
See all newsBrief: Shandong Boan Biotechnology Says CDE Clears IND Application For BA1203
Brief: Shandong Boan Biotechnology Co Says Industrial Bank Financial Leasing Will Purchase Leased Assets From Co
Brief: Shandong Boan Biotechnology Announces CDE IND Application Acceptance For TLLA/IL-23 Bispecific Antibody BA2201
Brief: Shandong Boan Biotechnology Expects Net Loss Attributable Of RMB79 Million-RMB89 Million
Brief: Shandong Boan Biotechnology Submits BLA For BA9101 To Anvisa In Brazil